Live updates: Bitcoin, gold and tech futures edge higher as markets await U.S. jobs report
Bitcoin trades above $86,000 as gold and tech futures rise, with investors expecting 90,000 new U. jobs and unemployment to hold at 4.
MARKETS
U.S. stock-market moves, S&P 500 and company action, Fed rates, economic data, White House policy, analyst views and market strategy
Bitcoin trades above $86,000 as gold and tech futures rise, with investors expecting 90,000 new U. jobs and unemployment to hold at 4.
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
One financial expert is turning away from safe-haven assets, even as real yields reach 2.
Rolling coverage of the latest economic and financial news UK diesel price hits record high of £2 a litre Core inflation in the eurozone also inched up last month. Inflation, excluding energy, food, alcohol & tobacco, rose to 2.
Key PointsShopify continues to solidify its leadership as an online shopping platform.
Oil prices fell sharply on Friday as Europe moved closer to another emergency stock release under pressure from the Trump administration, with WTI dropping nearly 4% and Brent falling below $100. ET, WTI was trading at $89.
Investors are looking to the nonfarm jobs report, which is considered the ultimate monthly health check for the U.
The report says: “Jobs report to offer brief relief from bond selloff.
Source description unavailable; open the original report for details.
(RTTNews) - French stocks gained ground in positive territory on Friday as weak oil prices helped lift sentiment even as concerns about Middle East tensions lingered.
Key PointsIf a bear market is coming, an AI downturn will be a major factor.
September provided a reset for stocks, pointing to a good end to the year, says Scott Rubner
Heavy selling this week pushed 10-year US Treasury yields to their highest level since 2002
In recent trading, shares of Phillips 66 (Symbol: PSX) have crossed above the average analyst 12-month target price of $258. 85, changing hands for $264.
Key PointsViking Therapeutics' VK2735 shows strong clinical promise and market potential.